MedTech Strategist's complimentary Community Blog focuses on the people and the passions that drive the global medical device industry. Sign up for our e-Newsletter to receive new articles and video interviews directly to your inbox.
e-Newsletter Browse
FDA lends a hand to companies pursuing De Novo authorization. Excerpted from Pathways’ Picks October 21: CDRH Hiring, EU Reform Timeline, AI Policy Plans, and More.
Medtech companies, weighed down by depressed stock prices and market challenges, are under intense pressure to step out of their comfort zones and make bets on innovation that will drive their future. Excerpted from our recent feature article, Despite Headwinds, A Nascent Medtech Rebound Is Fueling M&A.
FDA lends a hand to companies pursuing De Novo authorization. Excerpted from Pathways’ Picks October 21: CDRH Hiring, EU Reform Timeline, AI Policy Plans, and More.
Medtech companies, weighed down by depressed stock prices and market challenges, are under intense pressure to step out of their comfort zones and make bets on innovation that will drive their future. Excerpted from our recent feature article, Despite Headwinds, A Nascent Medtech Rebound Is Fueling M&A.